Vaishali Parab

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Hartmut Koeppen, Wei Yu, Jiping Zha et al. · Clinical Cancer Research · 2014 · 133 citations · Full text

Medicine, Oncology, Pharmacology +17

Crystalline Antibody‐Laden Alginate Particles: A Platform for Enabling High Concentration Subcutaneous Delivery of Antibodies

Amir Erfani, Jeremy M. Schieferstein, Paul Reichert et al. · Advanced Healthcare Materials · 2023 · 26 citations · Full text

Pharmacy, Biomedical Engineering, Pharmaceutics +17

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

Elicia Penuel, Congfen Li, Vaishali Parab et al. · Molecular Cancer Therapeutics · 2013 · 22 citations

Medicine, Oncology, Pharmacology +16

Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC).

Wenjing Yu, Ajay Pandita, Elicia Penuel et al. · Journal of Clinical Oncology · 2011 · 15 citations

Medicine, Oncology, Pharmacology +17

Toward a CRISPR-based mouse model of <i>Vhl</i> -deficient clear cell kidney cancer: Initial experience and lessons learned

Laura Stransky, Wenhua Gao, Laura S. Schmidt et al. · Proceedings of the National Academy of Sciences · 2024 · 10 citations · Full text

Medicine, Molecular Genetics, Oncology +17